secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001104659-25-021990
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alumis reports positive 52-week Phase 2 OLE data for ESK-001 in plaque psoriasis at AAD 2025
--------------------------------------------------------------------------------

- ESK-001 40 mg BID achieved PASI 90 61.3%, PASI 100 38.8%, sPGA 0 38.8% at Week 52 (mNRI, n=80).
- Responses sustained or improved vs Week 12; 80% of ≥PASI-75 responders at Week 12 maintained or improved at Week 52.
- No new safety findings; most TEAEs mild-to-moderate and self-limited.
- Phase 3 ONWARD program ongoing; topline data expected Q1 2026.
- Patient-reported outcomes: DLQI 0/1 61.3% and itch NRS≤4 81.3% at Week 52.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/0001104659-25-021990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-021990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer